SAN ANTONIO, Texas--(BUSINESS WIRE)--A new economic study found that adding CyPath® Lung, bioAffinity Technologies’ noninvasive test for detection of early-stage lung cancer, to the standard of care ...
Small cell lung cancer (SCLC) is a fast-growing cancer that develops in cells within the lung. A range of medical tests and procedures are available to help doctors diagnose SCLC and create an ...
CyPath® Lung test affirmed physician’s assessment that the nodule could be inflammation, not cancer; nodule resolved upon follow-up scan Noninvasive CyPath® Lung performed with 92% sensitivity, 87% ...
bioAffinity Technologies Inc. BIAF stock is trading higher on Tuesday as the company announced plans to advance the application of its CyPath Lung test. The company is pursuing the diagnostic tool for ...
SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced that unit ...
SAN ANTONIO, October 07, 2025--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, ...
When people think about annual health check-ups after 40, they usually focus on blood pressure, cholesterol, blood sugar and heart health. However, doctors say one vital organ is often overlooked - ...
Study by BAMC’s Michael Morris, M.D., and VA’s Sheila Habib, M.D., evaluated potential economic impact of CyPath® Lung for the early detection of lung cancer “Our study suggests the potential for a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results